Amy Wilson

Quantum Leap Healthcare Collaborative

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Quantum Leap Healthcare Collaborative

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Creighton University

Research Subjects

Research Interests

Amy Wilson has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

Adam L. Asare
19Quantum Leap Healthcare Collaborative, San Francisco, California
13 shared publications
Amy Jo Chien
University of California, San Francisco, San Francisco, USA
13 shared publications
Amy S. Clark
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania , Philadelphia, PA
13 shared publications
Andres Forero-Torres
University of Alabama at Birmingham, Birmingham, Alabama
13 shared publications
Angela DeMichele
University of Pennsylvania, Philadelphia, PA
13 shared publications
Anne M. Wallace
Department of Surgery, University of California San Diego, San Diego, CA 92093, USA
13 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Trebananib vs Control pCR–Biomarker Associations
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Trebananib vs Control pCR–Biomarker Associations
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Representativeness of Study Participants
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Representativeness of Study Participants
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Trebananib vs Control pCR–Biomarker Associations
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Trebananib vs Control pCR–Biomarker Associations
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Using Contemporary Controls and Adjusting for Time Trends in I-SPY2: The Time Machine
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Using Contemporary Controls and Adjusting for Time Trends in I-SPY2: The Time Machine
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Representativeness of Study Participants
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Representativeness of Study Participants
Open Access
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms
Website
Google Scholar
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
by Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, et al.
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms

Show all